In AML, the presence of ITDs structurally interferes with the JMD-mediated autoinhibition, allowing FLT3 to maintain or switch to its active conformation even in the absence of FLT3L binding [21]. This evidence concerns the gene FLT3 and acute myeloid leukemia.